Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Radiation. University Hospital Lausanne, Lausanne, Switzerland

Survival: 21.7 months
Toxicity Grade:
Treatments: Chemotherapy
Drugs: Temodar
Country: Switzerland
City/State/Province: Lausanne
Hospital: University Hospital Lausanne
Journal: Link
Date: 3/2005

Patients: This trial involved 206 patients with glioblastoma. Demographic information on the patients was not reported. The patients were randomly divided into two groups. In addition, all patients were categorized based on the level of methylation of the promoter for the gene MGMT; 46 patients in each group had methylated promoters. MGMT methylation is associated with longer survival for glioblastoma patients.

Treatment: Group B (100 patients) received radiotherapy and one chemotherapeutic agent: temozolomide.

Toxicity: Toxicities were not reported in this study.

Results: The focus of this report was to show any correlation in response to temozolomide and the methylation of the MGMT promoter.

Among patients without a methylated MGMT promoter, the overall survival for Group B(chemotherapy + radiotherapy) was 12.7 months. Among patients with a methylated MGMT promoter, the overall survival for Group B (chemotherapy + radiotherapy) was 21.7 months.

The authors concluded that MGMT methylation was a predictor for long-term survival.

Support: Although several authors disclosed receiving consultants fees, no commercial sponsorship of this study was discussed.

Correspondence: Monika E. Hegi, Ph.D.

E-mail to a Friend Email Physician More Information